Company: BLCO
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001860742-25-000004
Chunk: 11

Company: Bausch & Lomb Corp
Filing Date: 2025-02-19
Form: 10-K
Item: Item 7
Chunk 11
---
 and accounted for less than 1% of our total revenues in 2024 and approximately 1% of our total revenues in 2023. While we expect our risk of LOE to be limited over the next five years, this could change based on, among other things, successful challenge to our patents, settlement of existing or future patent litigation and at-risk generic launches. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.In addition, in connection with our Lumify®, PreserVision®, Vyzulta® and Lotemax® SM products, we have commenced ongoing infringement proceedings against potential generic competitors or other potential infringers in the U.S. If we are not successful in these proceedings, we may face increased generic competition for these products. The PreserVision® U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. PreserVision® products accounted for approximately 6% and 7% of our total revenues in 2024 and 2023, respectively. While PreserVision® and Lumify® are (or were) the subjects of certain ongoing and past patent infringement proceedings, the Company cannot predict the magnitude or timing of a loss of exclusivity impact from PreserVision® and Lumify® as these are OTC products, and thus, the impact is not expected to be as significant as the LOE of a branded pharmaceutical product.See Note 19, “LEGAL PROCEEDINGS” to our audited Consolidated Financial Statements for further information.

66

RESULTS OF OPERATIONSOur operating results for the years 2024, 2023 and 2022 were as follows:Years Ended December 31,Change(in millions)2024202320222023 to 20242022 to 2023RevenuesProduct sales$4,774 $4,131 $3,746 $643 $385 Other revenues17 15 22 2 (7)4,791 4,146 3,768 645 378 ExpensesCost of goods sold (excluding amortization and impairments of intangible assets) (Note 3)1,868 1,640 1,511 228 129 Cost of other revenues4 2 8 2 (6)Selling, general and administrative (